Ninlaro (Ixazomib Citrate)

Ixazomib citrate, the active ingredient in Ninlaro, is a proteasome inhibitor presented as an oral tablet for oral use. It treats multiple myeloma in combination with lenalidomide and dexamethasone in adult patients.

GNH USA supplies Ninlaro as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

Ninlaro is a proteasome inhibitor used in the treatment of multiple myeloma, either as initial therapy or in relapsed/refractory disease.

- Multiple myeloma (initial therapy): improves progression‑free survival when combined with lenalidomide and dexamethasone. - Multiple myeloma (relapsed/refractory): provides an oral option that can extend disease control in patients who have received prior therapies. - Multiple myeloma (maintenance): may be used as part of a maintenance regimen to sustain response after induction therapy.

Common side effects are typically mild to moderate and may affect treatment tolerability.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools, often transient. - Fatigue: general tiredness or lack of energy. - Constipation: reduced bowel movements. - Decreased appetite: reduced desire to eat. - Peripheral edema: mild swelling of extremities.

Serious or Rare Side Effects: - Neutropenia: low neutrophil count increasing infection risk. - Thrombocytopenia: reduced platelet count leading to bleeding. - Severe infections: opportunistic or bacterial infections. - Pulmonary embolism: blood clot in lung vessels. - Cardiac failure: reduced heart function. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should assess baseline health status and monitor for specific risks.

- Monitor blood counts: regular CBC to detect neutropenia or thrombocytopenia. - Assess hepatic function: liver enzymes should be checked prior to and during treatment. - Evaluate infection risk: screen for active infections and vaccinate when appropriate. - Use caution in cardiac disease: monitor for signs of heart failure. - Contraindicated in pregnancy: safety not established; avoid use in pregnant patients. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Ixazomib may interact with other medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A inducers (e.g., rifampin, carbamazepine): may reduce ixazomib exposure. - Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin): may increase ixazomib levels. - Antacids containing aluminum or magnesium: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Narrow‑therapeutic‑index CYP3A substrates (e.g., tacrolimus, cyclosporine): monitor drug levels. - Anticoagulants (e.g., warfarin): watch for altered coagulation parameters. - Immunosuppressants (e.g., mycophenolate): increased risk of infection, monitor closely.